CELL & GENE THERAPY PRODUCTS
MANUFACTURING, QUALITY AND REGULATORY CONSIDERATIONS
EUROPE 2026

KNOWLEDGE SHARING AND **CAPACITY BUILDING**

- *Leveraging prior knowledge is powerful* when used together with solid scientific justification.
- Novel methods and insights lead to *stronger and more efficient control strategies*.
- *Advances in genetic engineering and automation* enable the development of off-the-shelf and autologous cell therapies.
- *Assess the potential impact of individual changes* with a step-wise approach, take along functional potency, and don't look at one CQA in isolation.

CGTP EUROPE 2026 **BY THE NUMBERS**

Total Attendees
87

First-Time Attendees
42

Regulators Participated
21

Company Participation
51

Country Participation
16

Austria | Belgium | Denmark | France | Germany | Israel | Italy | Japan | Netherlands | Norway | Portugal | Spain | Sweden | Switzerland | United Kingdom | United States

CASSS RESOURCES

Looking for more past meeting content?

Speaker slides, roundtable notes, and video presentations can be accessed through **Papers and Presentations** and **CASSS On Demand** on our website. **www.casss.org**

CASSS
SHARING SCIENCE **SOLUTIONS**